Tissuemed are pleased to announce that Dr. David Mandley has been appointed as the company’s new CEO. David has worked for over 10 years at Tissuemed and he has been a Director of the Company for four years. Prior to his appointment as Tissuemed’s CEO, David had responsibility for Tissuemed’s Regulatory and Quality functions and has also travelled extensively on behalf of the Company to meet the surgeons who trial our potential new products. In this role he has also come to know many of our overseas distributors. David takes over as CEO from Jeremy Sampson, who has acted as temporary CEO for the last four months. Jeremy, a board member for over three years becomes Tissuemed’s Deputy Chairman.